Brent Kreider

Company: Biomed Valley Discoveries

Job title: President

Seminars:

Ulixertinib, a Clinically Proven Safe & Effective ERK1/2 Inhibitor with Combination Therapy Potential for Overcoming Resistance via Reactivation of the MAPK Pathway 4:15 pm

• Safe and effective targeting of ERK1/2 in humans is possible with ulixertinib • ERK inhibition provides the backbone for vertical combination treatment to overcome numerous MAPK reactivating resistance mechanisms • ERK inhibition remains a critical option to be explored for patient benefit, both as first-line and to overcome RAS inhibitor resistanceRead more

day: Day One